NCT03623373 2026-03-30
Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
Washington University School of Medicine
Phase 2 Completed
Clinical Trials
11 trialsNCT02337829 2026-01-08
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Acerta Pharma BV
Phase 2 Completed
NCT04883749 2025-06-08
CLL-Frail
German CLL Study Group
Phase 2 Completed
NCT04402138 2025-05-13
Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT03787264 2024-12-30
CLL2-BAAG
German CLL Study Group
Phase 2 Completed
NCT03788291 2024-09-26
Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
University of Rochester
Phase 2 Completed
NCT02362048 2019-10-01
KEYNOTE144
Acerta Pharma BV
Phase 2 Completed
NCT02537444 2019-09-25
Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)
Acerta Pharma BV
Phase 2 Completed
NCT02448303 2019-09-12
KEYNOTE166
Acerta Pharma BV
Phase 2 Completed
NCT02454179 2019-09-12
KEYNOTE147
Acerta Pharma BV
Phase 2 Completed
NCT02351739 2019-09-10
KEYNOTE143
Acerta Pharma BV
Phase 2 Completed